EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer’s Disease

Hina Kanwal iD, Moris Sangineto iD, Martina Ciarnelli, Pasqualina Castaldo iD, Rosanna Villani iD, Antonino Davide Romano iD, Gaetano Serviddio iD, Tommaso Cassano iD

International Journal of Molecular Sciences · 05.04.2024 · 25 (7) · 4050

DOI: 10.3390/ijms25074050 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.04.2024. Verfasst von Hina Kanwal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project “HEAL ITALIA-Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine-Cod, European Union “NextGenerationUE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD), the most common neurodegenerative disease (NDD), is characterized by chronic neuronal cell death through progressive loss of cognitive function. Amyloid beta (Aβ) deposition, neuroinflammation, oxidative stress, and hyperphosphorylated tau proteins are considered the hallmarks of AD pathology. Different therapeutic approaches approved by the Food and Drug Administration can only target a single altered pathway instead of various mechanisms that are involved in AD pathology, resulting in limited symptomatic relief and almost no effect in slowing down the disease progression. Growing evidence on modulating the components of the endocannabinoid system (ECS) proclaimed their neuroprotective effects by reducing neurochemical alterations and preventing cellular dysfunction. Recent studies on AD mouse models have reported that the inhibitors of the fatty acid amide hydrolase (FAAH) and monoacylglycerol (MAGL), hydrolytic enzymes for N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), respectively, might be promising candidates as therapeutical intervention. The FAAH and MAGL inhibitors alone or in combination seem to produce neuroprotection by reversing cognitive deficits along with Aβ-induced neuroinflammation, oxidative responses, and neuronal death, delaying AD progression. Their exact signaling mechanisms need to be elucidated for understanding the brain intrinsic repair mechanism. The aim of this review was to shed light on physiology and pathophysiology of AD and to summarize the experimental data on neuroprotective roles of FAAH and MAGL inhibitors. In this review, we have also included CB1R and CB2R modulators with their diverse roles to modulate ECS mediated responses such as anti-nociceptive, anxiolytic, and anti-inflammatory actions in AD. Future research would provide the directions in understanding the molecular mechanisms and development of new therapeutic interventions for the treatment of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeurodegenerative DiseasesUnited StatesAnimalsMiceAmyloid beta-PeptidesEndocannabinoidsNeuroinflammatory Diseases

Stichwörter der Autor:innen

Alzheimer’s diseaseCB2R)cannabinoid receptors (CB1Rendocannabinoid systemfatty acid amide hydrolase (FAAH)monoacylglycerol (MAGL)neurodegenerative diseases

Substanzen

Amyloid beta-PeptidesEndocannabinoids

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
  • Department of Biomedical Sciences and Public Health, School of Medicine, University "Politecnica delle Marche", 60126 Ancona, Italy.

ORCID-Profile: Hina Kanwal, Moris Sangineto, Pasqualina Castaldo, Rosanna Villani, Antonino Davide Romano, Gaetano Serviddio, Tommaso Cassano

Förderung

  • Project “HEAL ITALIA-Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine-Cod
  • European Union “NextGenerationUE

Zitieren

APA

Kanwal, H., Sangineto, M., Ciarnelli, M., Castaldo, P., Villani, R., Romano, A. D., Serviddio, G., & Cassano, T. (2024). Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer’s Disease. International Journal of Molecular Sciences, 25(7), 4050. https://doi.org/10.3390/ijms25074050

Vancouver

Kanwal H, Sangineto M, Ciarnelli M, Castaldo P, Villani R, Romano AD, et al. Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer’s Disease. International Journal of Molecular Sciences. 2024;25(7):4050. doi:10.3390/ijms25074050

BibTeX
@article{Kanwal2024,
  author = {Kanwal, Hina and Sangineto, Moris and Ciarnelli, Martina and Castaldo, Pasqualina and Villani, Rosanna and Romano, Antonino Davide and Serviddio, Gaetano and Cassano, Tommaso},
  title = {Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer’s Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {7},
  pages = {4050},
  doi = {10.3390/ijms25074050}
}
Kostenlos starten →